Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LNTH

DatePrice TargetRatingAnalyst
12/18/2024$143.00Buy
Goldman
9/3/2024$175.00Buy
Redburn Atlantic
7/10/2024$100.00 → $130.00Mkt Outperform
JMP Securities
12/18/2023Outperform → Mkt Perform
William Blair
12/4/2023$100.00Outperform
TD Cowen
9/29/2023Outperform
William Blair
3/8/2023$120.00Mkt Outperform
JMP Securities
11/30/2022Outperform
SVB Leerink
More analyst ratings

$LNTH
Press Releases

Fastest customizable press release news feed in the world

See more
  • Lantheus Reports Fourth Quarter and Full Year 2024 Financial Performance

    Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 million for the fourth quarter and full year 2024GAAP fully diluted loss per share of $(0.17) and earnings per share of $4.36 for the fourth quarter and full year 2024Adjusted fully diluted earnings per share of $1.59 and $6.76 for the fourth quarter and full year 2024PYLARIFY exceeds $1 billion in net sales and becomes first ever blockbuster radiodiagnosticCompany announces a series of strategic asset and in-licensing deals that is expected to diversify its portfolio with early- to late-stage assets that position the company for continued growth in high

    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Lantheus to Present at Upcoming Investor Conferences

    BEDFORD, Mass., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced members of its management team will present at the following upcoming investor conferences. B. Riley Securities Precision Oncology & Radiopharma Day in New York on February 28TD Cowen 45th Annual Health Care Conference in Boston on March 4 at 2:30 pm ETLeerink Global Healthcare Conference 2025 in Miami on March 11 at 1:40 pm ET A live webcast will be available for the TD Cowen 45th Annual Health Care Conference and Leerink

    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Lantheus to Host Fourth Quarter and Full Year 2024 Earnings Conference Call and Webcast on February 26, 2025, at 8:00 a.m. Eastern Time

    BEDFORD, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2025, to discuss its financial and operating results for the fourth quarter and full year of 2024. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least

    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$LNTH
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$LNTH
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$LNTH
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$LNTH
SEC Filings

See more

$LNTH
Leadership Updates

Live Leadership Updates

See more
  • Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member

    BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus' Board of Directors ("Board"), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board's Science and Technology Committee, where her proven track record i

    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Lantheus Appoints Julie Eastland as New Board Member

    BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors ("Board"), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent. "We are thrilled to welcome Julie Eastland t

    $DVAX
    $LNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Lantheus Appoints Jamie Spaeth as Chief People Officer

    BEDFORD, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Jamie Spaeth to its Executive Team as Chief People Officer. "We're excited to have Jamie join Lantheus as we continue to harness our team's potential to deliver innovative solutions to serve patients and healthcare professionals," said Dan Niedzwiecki, Chief Administrative Officer of Lantheus. "At Lantheus, our people drive our success, and Jamie's proven leadership and expertise will foster a collaborativ

    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$LNTH
Financials

Live finance-specific insights

See more
  • Lantheus Reports Fourth Quarter and Full Year 2024 Financial Performance

    Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 million for the fourth quarter and full year 2024GAAP fully diluted loss per share of $(0.17) and earnings per share of $4.36 for the fourth quarter and full year 2024Adjusted fully diluted earnings per share of $1.59 and $6.76 for the fourth quarter and full year 2024PYLARIFY exceeds $1 billion in net sales and becomes first ever blockbuster radiodiagnosticCompany announces a series of strategic asset and in-licensing deals that is expected to diversify its portfolio with early- to late-stage assets that position the company for continued growth in high

    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Lantheus to Host Fourth Quarter and Full Year 2024 Earnings Conference Call and Webcast on February 26, 2025, at 8:00 a.m. Eastern Time

    BEDFORD, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2025, to discuss its financial and operating results for the fourth quarter and full year of 2024. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least

    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader

    Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVY™, a registrational-stage diagnostic asset, targeting neuroendocrine tumors that is complementary to Lantheus' therapeutic agent, PNT2003 Expands oncology radiopharmaceutical pipeline with multiple clinical and pre-clinical theranostic pairs Company reaffirms Full-Year and Fourth Quarter, 2024 financial guidance Company to host conference call on January 28, 2025, at 8:30 AM ET BEDFORD, Mass., Jan. 28, 2025 /PRNewswire/ -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company c

    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$LNTH
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more